<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    8411526
   </pmid>
   <datecreated>
    <year>
     1993
    </year>
    <month>
     11
    </month>
    <day>
     01
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1993
    </year>
    <month>
     11
    </month>
    <day>
     01
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2010
    </year>
    <month>
     03
    </month>
    <day>
     24
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0098-7484
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       270
      </volume>
      <issue>
       15
      </issue>
      <pubdate>
       <year>
        1993
       </year>
       <month>
        Oct
       </month>
       <day>
        20
       </day>
      </pubdate>
     </journalissue>
     <title>
      JAMA : the journal of the American Medical Association
     </title>
     <isoabbreviation>
      JAMA
     </isoabbreviation>
    </journal>
    <articletitle>
     Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.
    </articletitle>
    <pagination>
     <medlinepgn>
      1826-31
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To determine pneumococcal polysaccharide vaccine efficacy in selected populations at risk for serious pneumococcal infection for whom vaccination is currently recommended and to assess duration of protection after vaccination.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Vaccine efficacy was estimated using indirect cohort analysis to compare the proportion of pneumococcal infections caused by serotypes included in the vaccines of vaccinated and unvaccinated persons who were identified during 14 years of national surveillance.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Hospital laboratories in the United States that submitted pneumococcal isolates to the Centers for Disease Control and Prevention between May 1978 and April 1992.
     </abstracttext>
     <abstracttext label="PARTICIPANTS" nlmcategory="METHODS">
      A total of 2837 persons older than 5 years who had pneumococcus isolated from blood or cerebrospinal fluid.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Overall efficacy for preventing infection caused by serotypes included in the vaccine was 57% (95% confidence interval [CI], 45% to 66%). Efficacy among persons with diabetes mellitus was 84% (95% CI, 50% to 95%); with coronary vascular disease, 73% (95% CI, 23% to 90%); with congestive heart failure, 69% (95% CI, 17% to 88%); with chronic pulmonary diseases, 65% (95% CI, 26% to 83%); and with anatomic asplenia, 77% (95% CI, 14% to 95%). Efficacy was not documented for patients with alcoholism or cirrhosis, sickle cell disease, chronic renal failure, lymphoma, leukemia, or multiple myeloma, although sample sizes were small for these groups. Efficacy for immunocompetent persons older than 65 years was 75% (95% CI, 57% to 85%). Efficacy did not decline with increasing interval after vaccination: 5 to 8 years after vaccination it was 71% (95% CI, 24% to 89%), and 9 years or more after vaccination it was 80% (95% CI, 16% to 95%).
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Intensified efforts to improve pneumococcal vaccine coverage among certain populations for whom vaccination is currently recommended is indicated, but universal revaccination is not warranted at this time.
     </abstracttext>
    </abstract>
    <affiliation>
     Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Butler
      </lastname>
      <forename>
       J C
      </forename>
      <initials>
       JC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Breiman
      </lastname>
      <forename>
       R F
      </forename>
      <initials>
       RF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Campbell
      </lastname>
      <forename>
       J F
      </forename>
      <initials>
       JF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lipman
      </lastname>
      <forename>
       H B
      </forename>
      <initials>
       HB
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Broome
      </lastname>
      <forename>
       C V
      </forename>
      <initials>
       CV
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Facklam
      </lastname>
      <forename>
       R R
      </forename>
      <initials>
       RR
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     JAMA
    </medlineta>
    <nlmuniqueid>
     7501160
    </nlmuniqueid>
    <issnlinking>
     0098-7484
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Bacterial Vaccines
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Pneumococcal Vaccines
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged, 80 and over
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Bacterial Vaccines
     </descriptorname>
     <qualifiername majortopicyn="N">
      standards
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child, Preschool
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cohort Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Evaluation
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pneumococcal Infections
     </descriptorname>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
     <qualifiername majortopicyn="N">
      microbiology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pneumococcal Vaccines
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Population Surveillance
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Serotyping
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Streptococcus pneumoniae
     </descriptorname>
     <qualifiername majortopicyn="Y">
      classification
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N" type="Geographic">
      United States
     </descriptorname>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Vaccination
     </descriptorname>
     <qualifiername majortopicyn="N">
      standards
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1993
     </year>
     <month>
      10
     </month>
     <day>
      20
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1993
     </year>
     <month>
      10
     </month>
     <day>
      20
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1993
     </year>
     <month>
      10
     </month>
     <day>
      20
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     8411526
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

